Form 8-K Salarius Pharmaceuticals For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Salarius Pharmaceuticals faces Nasdaq delisting over stock price
January 2, 2026 5:16 PM ESTSalarius Pharmaceuticals, Inc. (NASDAQ: SLRX) received notice from Nasdaq on December 31, 2025, stating the company fails to meet minimum bid price requirements for continued listing on The Nasdaq Capital Market.
The company's stock closed below $1.00 per share for 30 consecutive business days, violating Nasdaq... More
